



## **Mersana Therapeutics to Present at Upcoming Investor Conferences**

September 6, 2022

CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will present at two upcoming investor conferences. Details are as follows:

### **Morgan Stanley 20<sup>th</sup> Annual Global Healthcare Conference**

Format: Fireside Chat

Date/Time: Monday, September 12, 2022, at 4:15 p.m. Eastern Time

### **Baird 2022 Global Healthcare Conference**

Format: Fireside Chat

Date/Time: Tuesday, September 13, 2022, at 2:00 p.m. Eastern Time

A live webcast of the fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference will be available on the Investors & Media section of Mersana's website at [www.mersana.com](http://www.mersana.com). An archived replay will be available for approximately 90 days following the event.

### **About Mersana Therapeutics**

Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana's lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b that is being studied in UPLIFT, a single-arm registrational trial in patients with platinum-resistant ovarian cancer; UPGRADE, a Phase 1/2 umbrella trial evaluating UpRi in combination with other ovarian cancer therapies; and UP-NEXT, a Phase 3 clinical trial of UpRi as monotherapy maintenance following treatment with platinum doublets in recurrent platinum-sensitive ovarian cancer. Mersana is also advancing XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2), in addition to other earlier-stage assets. In addition, multiple partners are using Mersana's platforms to advance their ADC pipelines. Mersana Therapeutics was named among the 2021 Top Places to Work in Massachusetts by The Boston Globe. Mersana routinely posts information that may be useful to investors on the "Investors and Media" section of its website at [www.mersana.com](http://www.mersana.com).

### **Contact:**

Jason Fredette

617-498-0020

[jason.fredette@mersana.com](mailto:jason.fredette@mersana.com)